News
Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test  Quarterly Update Conference Call and Webcast Today at 4:30 p.m. ET CASTLE ROCK, Colo., March 26, 2012 — Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its rapid, protein biomarker-based appendicitis test, APPY1, today provided an update on its clinical and commercial activities. The Company continues to enroll patients into its ongoing pivotal U.S. clinical study [...] Read more…
Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its rapid, protein biomarker-based appendicitis test, APPY1, today announced it will provide a fourth quarter business update on Tuesday, March 26, 2013, at 4:30 p.m. ET. Read more…
Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE-Marked blood-based appendicitis test, APPY1, today announced it has executed two additional commercial development agreements as part of the initial phase of the European launch. Read more…
Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its blood-based appendicitis test, APPY1, today announced that it will present at the 25th Annual ROTH Conference, to be held March 17-20, 2013, at the Ritz-Carlton Laguna Niguel in Dana Point, CA. Read more…
Venaxis, Inc. today announced that its presentation at the 2013 BIO CEO and Investor Conference, to be held February 11-12, 2013, at the Waldorf Astoria Hotel in New York, has been rescheduled for Tuesday, February 12, 2013. Read more…
Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its blood-based appendicitis test, APPY1, today announced it has signed its first European commercial development agreement with Netherlands-based EMELCA Bioscience for the initial phase of Venaxis’ EU launch. Read more…
Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its blood-based appendicitis test, APPY1, today announced that Steve Lundy, President and Chief Executive Officer, will present at RetailInvestorConferences.com. Read more…
Venaxis, Inc. (Nasdaq: APPY) today announced that it will present at the 2013 BIO CEO and Investor Conference, to be held February 11-12, 2013, at the Waldorf Astoria Hotel in New York. Read more…
Venaxis, Inc. today announced that it has begun enrolling patients into its pivotal clinical study in the United States. Read more…
Venaxis, Inc. today announced it has fulfilled the requirements for CE Marking in Europe for APPY1, the Company’s blood-based appendicitis test. Initial commercialization in Europe is planned to commence in the first quarter 2013 in key territories, including the UK, Italy, France, Germany and Benelux countries. Read more…
